European PKU group annual symposium em Lisboa 25 e 26 de Março

European PKU group annual symposium

March 25th - 26th, 2011 in Lisbon, Portugal

Aim of the symposium

There is no doubt that the early identification of PKU and prompt intervention have allowed most individuals to escape from mental retardation. Dietary restriction of phenylalanine remains the mainstay of treatment but PKU is an active area of research and new treatment options are emerging that may reduce the burden of the difficult and restrictive diet on patients and their families.

The recent introduction of sapropterin dihydrochloride (BH4) into therapeutic use is likely to contribute to the management of PKU for a subset of patients who respond to this treatment. There is also an emerging need for evidence-based international guidelines to provide consensus concerning treatment initiation and determination of the response to therapy with sapropterin, as well as consensus on target blood Phe concentrations, and clarity on optimized treatment protocols for the management of PKU and HPA. For this reason Serono Symposia International Foundation and the European Phenylketonuria Group, continuing their series of successful meetings, has organized the 2011 Annual Symposium dedicated to PKU. The aim of the meeting is to review the most important outcomes of research in the field and to provide a forum for participants to discuss solutions that can optimize patient management in clinical practice.

Learning objectives

After attending this symposium, the participants will have up-to-date knowledge about:

• Pathophysiology of PKU
• Diagnosis, classification, and genetics of PKU
• Maternal and adult PKU
• Nutritional treatment
• Current trials in PKU
• Advances in PKU research on pharma-chaperons
• Other treatment options

General Information

Date: 25th - 26th of March, 2011
Venue: Corinthia Hotel
Av. Columbano Bordalo Pinheiro, n 105
Lisbon 1099-031, Portugal

Further information about European PKU group annual meeting